Early production of donor-derived CD4+ CD25+ regulatory T cells in patients given hematopoietic stem cell transplants  by Woodliff, J. et al.
49
EARLY PRODUCTION OF DONOR-DERIVED CD4 CD25 REGULA-
TORY T CELLS IN PATIENTS GIVEN HEMATOPOIETIC STEM CELL
TRANSPLANTS
Woodliff, J.1, Taylor, C.1, Douek, D.2, Margolis, D.1, Drobyski, W.1,
Johnson, B.1, Truitt, R.1 1. Departments of Pediatrics and Medicine,
Medical College of Wisconsin, Millwaukee, WI; 2. NIH Vaccine Re-
search Center, Bethesda, MD
In previous studies using murine models of BMT/DLI therapy,
we found that donor-BM-derived CD4 regulatory T cells (T-
REG) produced in the host thymus were responsible for suppres-
sion of DLI-associated GVHD. Based on our mouse data, we
hypothesized that failure of the host thymus to produce T-REG
cells after allogeneic BMT in humans would result in an increased
risk of GVHD after DLI therapy and an increased risk of chronic
GVHD. Here, we sought to identify, expand and functionally
characterize T-cells over time in patients given hematopoietic stem
cell transplants (HSCT). Peripheral blood (PB) was collected from
19 adult and 8 pediatric patients at 2, 4, 6 and 12 mo. post-
transplant. T-REG cells were identiﬁed by staining ﬁcoll-separated
PB cells for coexpression of CD4 and CD25. T-REG cells were
deﬁned phenotypically as CD4 cells with high levels of CD25
staining. 88% (22/25) of patients analyzed at 2 mo. had detectable
levels of CD4 CD25 cells. These cells persisted over time; only
two patients with detectable T-REG cells at 2 mo. lost them by 6
mo. Some, but not all, CD4 CD25 cells had high TREC levels
suggesting that they were recent thymic emigrants. We puriﬁed
CD4 CD25 cells and CD4 CD25- cells by cell sorting when
sufﬁcient PB was available and expanded them ex vivo using anti-
CD3/anti-CD28 conjugated Dynal beads and rIL-2. The ex-
panded CD4 CD25 cells were conﬁrmed as being of donor-
origin by VNTR analysis. Most were functional as shown by their
ability to suppress T cell proliferation when titrated into MLR
assays. Expanded CD4 CD25 cells from 5 of 8 patients sup-
pressed proliferation of T cells from the original HSC donor (i.e.,
autologous T cells) by 26-94% (R : T-REG  1:1). When donor
T cells were not available, unrelated T cells were used in the MLR
assays. Ex vivo expanded cells from 6 of 7 patients suppressed the
proliferation of the allogeneic responder T cells by 34-77% (R :
T-REG  1:1). Our results indicate that functional CD4
CD25 regulatory T cells of donor origin are present early after
HSCT in most patients. The patients, tissue source and histocom-
patibility of the HSCs used in this study were heterogeneous.
Determining whether the de novo generated T-REG cells are
sufﬁcient to mitigate GVHD will require a more homogeneous
patient group and longer follow-up. Adoptive transfer of T-REG
cells isolated from the HSCT donor and expanded ex vivo may be
necessary to more effectively modulate GVHD.
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LOW CIRCULATING DENDRITIC CELL COUNT AFTER ALLOGENEIC
STEM CELL TRANSPLANTATION (SCT) PREDICTS DEATH, RELAPSE,
AND ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
Reddy, V.1, Iturraspe, J.A.2, Tzolas, A.C.1, Meier-Kriesche, H.-U.1,
Schold, J.1, Greene, S.1, Wingard, J.R.1 1. University of Florida,
Department of Medicine, Gainesville, FL; 2. Lifesouth Community
Blood Centers, Department of Flow Cytometry, Gainesville, FL
Dendritic cells (DC) are key antigen presenting cells, with a
potential role in tumor vaccines. We investigated the hypothesis
that early reconstitution of DC around the time of engraftment
after allogeneic SCT improves survival. We also correlated DC
reconstitution with complications of relapse and AGVHD. Fifty
patients were transplanted between February 2000 and March
2003 with a median follow up of 501 days (range 136-1263). Most
patients received blood stem cells (92%), and the remainder bone
marrow, from HLA matched sibling donors for predominantly
high risk hematologic malignancies. Around the time of sustained
neutrophil engraftment of 500 cells/mm3, peripheral blood was
analyzed by ﬂow cytometry for DC as lineage negative, HLA-DR
positive, and further divided as DC1 (CD11c) and DC2
(CD123). Patients were divided into two groups of either low
(n  23) or high (n  27) absolute DC count based on clustering
technique determination. Patients with lower DC count (4.97
cells/mm3) had a signiﬁcantly worse survival by Kaplan-Meier
analysis (p  0.009), increased incidence of relapse (p  0.002), a
higher incidence of AGVHD onset (p  0.0005) and a composite
end point of relapse or death (p  0.002). A Cox-proportional
Hazard multivariate model adjusted for important covariates con-
ﬁrmed that low DC count is independently associated with death
(HR 3.8; 95% CI 1.3, 11.3; p  0.02), time to relapse (HR 10.2;
95% CI 2.2, 47.2; p  0.003) and in the development of severe
AGVHD (HR  2.7; 95% CI 1.2, 6.4; p  0.02). The sensitivity
and speciﬁcity of low DC count in predicting death or relapse after
transplantation is 73% and 75% respectively with a positive pre-
dictive value (PPV) of 70% and negative predictive value (NPV) of
78%. To further delineate DC functionally, we studied DC1 and
DC2 phenotypes, and the failure rates remained higher in the low
cell count groups. In addition, DC recovery was independent of
DC infused or patient DC counts prior to transplant. Our data
suggest that, at least for peripheral blood SCT, the number of DC
in the graft has no impact while the numbers of DC ultimately
reconstituted in the recipient make the difference. In summary, our
ﬁndings are unique for describing an early easily reproducible
clinical indicator for adverse clinical outcomes such as relapse,
death, and AGVHD after hematopoietic SCT. This ﬁnding should
allow for early recognition of patients and studies for potential
therapeutic interventions.
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REDUCED-INTENSITY CONDITIONING (RIC) REGIMENS RESULT IN
LOW PREVALENCE OF PREMATURE OVARIAN FAILURE (POF) IN
WOMEN UNDERWENT HEMATOPOIETIC STEM-CELL TRANSPLANTA-
TION (HST)
Cheng, Y.C., Saliba, R.M., Rondon, G., Giralt, S.A., Lu, K.H.,
Bodurka, D.C., Gershenson, D.M., Champlin, R.E., Ueno, N.T. The
University of Texas M. D. Anderson Cancer Center, Houston, TX
High-dose conditioning (HDC) regimens used for HST can
cause high incidence of POF among female transplant survivors.
POF results in uncomfortable postmenopausal symptoms and in-
fertility. In contrary, RIC regimens have resulted generally less
treatment-related toxicity and GVHD. Therefore, RIC regimens
are expected to have lower rate of POF in theory. However, the
actual prevalence is unknown. Of the 3,945 patients who under-
went HST between January 1987 and September 2001 at our
institution, 488 were female, aged 16–40 years at the transplant,
and had no history of breast or ovarian cancer. Of those patients,
413 (85%) had been given HDC regimens and 75 (15%) had been
given RIC regimens. Two hundred twelve patients (179 [43%] in
the HDC group and 33 [44%] in the RIC group) were alive at the
time of this cross-sectional study. Questionnaires on menstruation
history before and after HST were sent to 166 patients with
addresses on ﬁle; 89 (64%) of the 138 patients given HDC and 20
(71%) of the 28 given RIC replied. Age, disease status, and treat-
ment variables were statistically similar in patients who replied and
those who did not. Median follow-up among women who replied
was 75 months for the HDC group and 22 months for the RIC
group. Age, disease status, and treatment variables were also sta-
tistically similar in the HDC and RIC groups. Similar proportions
of women in each group (12 of 89 HDC and 4 of 20 RIC) reported
loss of ovarian function (deﬁned as loss of menstruation for 12
months or an FSH/LH level 20 IU/L) before HST. Ovarian
failure after HST was reported by 61 (79%) of those given HDC
vs. only 6 (37.5%) of those given RIC (P 0.007). Among patients
who retained their ovarian function after transplant, 4 in HDC and
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